All In Biotech

Drug Trial Radar · NCT05157945

ALTO-300 in Depression (ALTO-300-004)

AN OPEN-LABEL STUDY OF ALTO-300 IN ADULTS WITH MAJOR DEPRESSIVE DISORDER

Last checked: Nov 20, 2026Latest source record: Apr 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

148

Actual

Start

Feb 3, 2022

Primary completion

Apr 26, 2023

Study completion May 5, 2023

Sponsor

Lead sponsor
Alto NeuroscienceIndustry
Sponsor type
Industry
First posted
Dec 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-300.

Conditions

  • Major Depressive Disorder

Interventions

  • ALTO-300 PO TabletDrug

    One tablet daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To understand the relationship between baseline biology and change in the Montgomery-Asberg Depression Rating Scale (MADRS) with ALTO-300Time frame: Measured 6 times over 8 weeks
  2. To understand the relationship between baseline biology and change in the Clinical Global Impression scale - Severity (CGI-S) with ALTO-300Time frame: Measured 6 times over 8 weeks
  3. Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability of ALTO-300Time frame: From the signing of the ICF until the follow-up visit (up to 12 weeks)
  4. Number of Participants With Clinically Significant Vital Signs Abnormalities as a Measure of Safety and Tolerability of ALTO-300Time frame: From the signing of the ICF until the end-of-treatment visit (up to 11 weeks)]
  5. Number of Participants With Clinically Significant Laboratory Abnormalities as a Measure of Safety and Tolerability of ALTO-300Time frame: From the signing of the ICF until the end-of-treatment visit (up to 11 weeks)]

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Cerebral - Atlanta

    Atlanta, Georgia

  • Site 171

    Jackson, Mississippi

  • Cerebral - New York City

    New York, New York

  • Cerebral - Dallas

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.